No Data
No Data
No Data
No Data
No Data
Dongyao Pharmaceutical-B announced that it will achieve revenue of 781 million yuan in 2023, a 77% year-on-year increase
Dongyao Pharmaceutical-B (01875) announced its 2023 results. The group's revenue was approximately RMB 781 million, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630 million, an increase of 107% over the previous year. The main contribution came from a sharp increase in sales performance of the core product, Park Hsin Ting (bevacizumab injection). CDMO/CMO business revenue was RMB 141 million, up 94% year over year. Since there was no one-time authorization income for the full year of 2023 (RMB 54,151 million for the full year of 2022), excluding this factor, the revenue for the full year of 2023 is the same
新浪港股Mar 17 21:10 ET
Gelonghui Announcements Selected (Hong Kong Stocks) | Fuyao Glass (03606.HK) Announces Annual Results: Net Profit Increased by 18.37% to RMB 5.629 billion, with an estimated capital requirement of RMB 41,016 billion for the full year of 2024
[Today's Focus] Fuyao Glass (03606.HK) announced annual results: net profit increased by 18.37% to 5.629 billion yuan, with an estimated capital requirement of 41,016 billion yuan for 2024 Fuyao Glass (03606.HK) announced annual results. For the year ended December 31, 2023, the company consolidated revenue of RMB 33.161 billion, an increase of 18.02% over the same period of the previous year; achieved profit before tax of RMB 6.715 billion, an increase of 20.38% over the same period of the previous year, and achieved an annual profit of RMB 20.38% over the same period last year 5.629 billion yuan, compared to the previous year
Gelonghui FinanceMar 15 11:20 ET
Dongyao Pharmaceutical-B (01875.HK) announced annual results, a sharp increase in revenue of 77%, and the group's hematopoietic capacity continued to increase
Gelonghui March 15 | Dongyao Pharmaceutical-B (01875.HK) announced that in 2023, the Group's revenue was RMB 780,629 thousand, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630,207 thousand, an increase of 107% over the previous year. The main contribution was due to a significant increase in sales performance of the core product Park Xinting (bevacizumab injection). CDMO/CMO business revenue was RMB 140,898 thousand, up 94% year over year. Due to no one-time authorization income for the full year of 2023 (RMB 54,151 thousand for the full year of 2022)
Gelonghui FinanceMar 15 10:28 ET
TOT BIOPHARM-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Futu NewsMar 15 10:08 ET · Announcements
Dongyao Pharmaceutical-B (01875.HK) plans to hold a board meeting on March 15 to approve annual results
Gelonghui March 5 | Dongyao Pharmaceutical-B (01875.HK) announced that the company will hold a board meeting on March 15, 2024 (Friday) to consider and approve the Group's annual results for the year ended December 31, 2023, and to deal with other matters.
Gelonghui FinanceMar 5 03:46 ET
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) is now up more than 8%, and overseas authorized transactions for domestic ADCs are hot
Dongyao Pharmaceutical-B (01875) is currently up more than 8%. As of press release, it is up 8.12% to HK$2.13.
Zhitong FinanceDec 21, 2023 01:06 ET
No Data
No Data